Opus Genetics, Inc. (IRD)
| Market Cap | 384.68M +190.5% |
| Revenue (ttm) | 7.91M -45.9% |
| Net Income | -136.65M |
| EPS | -1.50 |
| Shares Out | 96.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 747,200 |
| Open | 4.145 |
| Previous Close | 4.060 |
| Day's Range | 3.800 - 4.170 |
| 52-Week Range | 1.700 - 7.070 |
| Beta | 0.80 |
| Analysts | Strong Buy |
| Price Target | 13.94 (+250.25%) |
| Earnings Date | Nov 10, 2026 |
About IRD
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets ... [Read more]
Financial Performance
In 2025, Opus Genetics's revenue was $14.20 million, an increase of 29.15% compared to the previous year's $10.99 million. Losses were -$49.59 million, -13.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for IRD stock is "Strong Buy." The 12-month stock price target is $13.94, which is an increase of 250.25% from the latest price.
News
Opus Genetics price target raised to $11 from $9 at RBC Capital
RBC Capital analyst Lisa Walter raised the firm’s price target on Opus Genetics (IRD) to $11 from $9 and keeps an Outperform rating on the shares. After positive data from…
Opus Genetics price target raised to $14 from $8 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Opus Genetics (IRD) to $14 from $8 and keeps a Buy rating on the shares. The company has multiple…
Opus Genetics reports Q3 EPS (46c), consensus (15c)
Reports Q3 revenue $1.14M, consensus $2.08M. “The last several months have marked a period of tremendous advancement for our leading gene therapy programs,” said George Magrath, Chief Executive Office...
Opus Genetics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
LCA5 pivotal data are expected next year, while BEST1 cohort two will test a higher dose in earlier-stage patients. Potential readouts across four programs and a targeted launch plan are supported by runway into 2029.
Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026 FDA Clearance of IND for OPGx-RDH12...
Opus Genetics Earnings release: Q3 2026
Opus Genetics released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Opus Genetics Quarterly report: Q3 2026
Opus Genetics has published its Q3 2026 quarterly earnings report on November 10, 2026.
Opus Genetics completes dosing in higher-dose Cohort 2 of BIRD-1 trial
Opus Genetics (IRD) announced the completion of dosing in the higher-dose Cohort 2 of BIRD-1, its ongoing Phase 1/2 clinical trial evaluating OPGx-BEST1 in patients with BEST1-related retinal diseases...
Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent bl...
Opus Genetics appoints Andrew Murphy as chief scientific officer
Opus Genetics (IRD) announced the appointments of Andrew Murphy as chief scientific officer and Jamie Lynne Hart as executive director, executive operations. Prior to joining Opus Genetics, Murphy ser...
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics announces FDA clearance of OPGx-RDH12 IND application
Opus Genetics (IRD) announced that the FDA has cleared its investigational new drug, or IND, application for OPGx-RDH12, an investigational gene therapy for the treatment of RDH12-associated Leber con...
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childh...
Opus Genetics Transcript: Chardan's 10th Annual Healthcare Conference
FDA approval of phentolamine brings a $10M milestone, while LCA5 dosing is underway and BEST1 Cohort 2 data are expected in Q2 2027. Current funding plans support five programs and runway into 2029, excluding voucher proceeds.
Opus Genetics Slides: Chardan's 10th Annual Healthcare Conference
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2026.
Opus Genetics reports FDA approval of phentolamine ophthalmic solution 0.75%
Opus Genetics (IRD) announced that the U.S. Food and Drug Administration has approved the company’s supplemental New Drug Application for phentolamine ophthalmic solution 0.75% for the treatment of pr...
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
FDA expands the approved use of phentolamine ophthalmic solution 0.75% to include age-related near vision impairment, which affects millions of adults in the United States Approval supported by positi...
Opus Genetics presents clinical findings from its OPGx-BEST1, OPGx-LCA5 programs
Opus Genetics (IRD) presented clinical findings from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026 in Rio de Janeiro, Brazil. The company presented findings from the…
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company's Phase 1/2 clinical trial, supporting further clinical development New ...
Opus Genetics to Present at the Chardan Annual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics management to meet with Oppenheimer
Meeting to be held in New York on October 19 hosted by Oppenheimer.
Opus Genetics price target raised to $17 from $10 at Jones
Jones raised the firm’s price target on Opus Genetics (IRD) to $17 from $10 and keeps a Buy rating on the shares following the OPGx-BEST1 data presentation. Microperimetry was the…
Opus Genetics Slides: Investor presentation
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.